NEW YORK, NY / ACCESSWIRE / June 27, 2017 / The Dow and S&P 500 eked out modest gains on Monday, despite a poor performance from the technology sector. The Dow Jones Industrial Average gained 0.07 percent to close at 21,409.55, while the S&P 500 Index rose 0.03 percent to close at 2,439.07. The tech-heavy NASDAQ Composite Index declined 0.29 percent to close at 6,247.15. The S&P 500 has gained approximately 8.9 percent in the first half of 2017. Some analysts are still predicting the upward trend to continue in the second half of 2017.

"When the 500's first-half price gain was between 7% and 12%?the market went on to record an average price rise of 5.1% during the second half and posted a positive performance an above-average 87% of the time," wrote CFRA's Chief Investment Strategist, Sam Stovall.

RDI Initiates Coverage on:

Exelixis, Inc.
https://ub.rdinvesting.com/news/?ticker=EXEL

Seattle Genetics
https://ub.rdinvesting.com/news/?ticker=SGEN

Exelixis' stock moved 4.71% higher Monday, to close the day at $24.90. The stock recorded a trading volume of 6,110,490 shares, which was above its three months average volume of 3,311,770 shares. In the last year Exelixis Inc.'s shares have traded in a range of 7.20 - 25.18. The share price has gained 245.83% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $20.39 is greater than its 200-day moving average of $19.92. Shares of Exelixis have gained approximately 67.0 percent year-to-date.

Access RDI's Exelixis Research Report at:
https://ub.rdinvesting.com/news/?ticker=EXEL

On Monday, shares in Seattle Genetics recorded a trading volume of 8,174,482 shares, which was above the three months average volume of 702,105 shares. The stock ended the day 8.41% lower at 56.55. The share price has gained 57.39% from its 52 week low with a 52 week trading range of 35.93 - 75.36.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $63.99 is greater than its 200-day moving average of $63.11. Shares of Seattle Genetics have gained approximately 7.16 percent year-to-date.

Access RDI's Seattle Genetics Research Report at:
https://ub.rdinvesting.com/news/?ticker=SGEN

Our Actionable Research on Exelixis, Inc. (NASDAQ: EXEL) and Seattle Genetics, Inc. (NASDAQ: SGEN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com